Curtis J. Henrich, Ph.D.
Team Member of:
Dr. Henrich coordinates bioassay development, high-throughput screening, and application of assays to natural products isolation within the Molecular Targets Program.
Coordination of bioassay development, high-throughput screening, and application of assays to natural products isolation.
- Biochem. Pharmacol.. 88: 313-21, 2014. [ Journal Article ]
- Phytochem Lett. 7: 42-45, 2014. [ Journal Article ]
High-throughput screening for identification of inhibitors of EpCAM-dependent growth of hepatocellular carcinoma cells.Chem Biol Drug Des. 82: 131-9, 2013. [ Journal Article ]
Isobutylhydroxyamides from the pericarp of Nepalese Zanthoxylum armatum inhibit NF1-defective tumor cell line growth.J. Nat. Prod.. 76: 59-63, 2013. [ Journal Article ]
- Nat Prod Rep. 30: 1284-98, 2013. [ Journal Article ]
Dr. Henrich received his Ph.D. in biochemistry from the University of Michigan (thesis research on erythrocyte senescence-related glycoconjugates). He conducted his postdoctoral research in Michigan and at the University of California, San Francisco, which was followed by 14 years in the biotechnology industry (Life Technologies, Inc. and a now defunct start-up called Aptus Pharmaceuticals). He joined the Molecular Targets Program (formerly, Molecular Targets Laboratory) in 2003 first as a Consultant, then as a Senior Scientist affiliated with Leidos Biomedical Research, Inc. (formerly, SAIC-Frederick, Inc.)
|Emad Darvishi Ph.D.||Postdoctoral Fellow (Visiting)|
|Emily Smith M.S.||Research Associate (Leidos)|
|Antony Wamiru||Senior Research Technician (Leidos)|
|Jennifer A. Wilson||Biological Lab Technician|
|Girma M. Woldemichael, Ph.D.||Scientist II (Leidos)|